Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...

Full description

Saved in:
Bibliographic Details
Published in:Antibodies (Basel)
Main Authors: Del Bano, Joanie, Chames, Patrick, Baty, Daniel, Kerfelec, Brigitte
Format: Artigo
Language:Inglês
Published: MDPI 2015
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6698871/
https://ncbi.nlm.nih.gov/pubmed/31557983
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antib5010001
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items